ePrints

Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transciption 1 (STAT1) mutation

Lookup NU author(s): Tariq AlShehri, Dr Desa Lilic

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

We demonstrate clinical utility of ruxolitinib, a JAK1/2 inhibitor, in CMC due to STAT1 gain-of-function mutation. We show functional data to explain this effect. This drug is a potentially a transformative therapy for these patients.

Publication metadata

Author(s): Higgins E, AlShehri T, McLeer MA, Feighery C, Lilic D, Irvine AD

Publication type: Article

Publication status: Published

Journal: Journal of Allergy and Clinical Immunology

Year: 2015

Volume: 135

Issue: 2

Pages: 551-553

Print publication date: 04/02/2015

Online publication date: 04/02/2015

Acceptance date: 02/02/2015

ISSN (print): 0091-6749

ISSN (electronic): 1097-6825

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/j.jaci.2014.12.1867

DOI: 10.1016/j.jaci.2014.12.1867

Altmetrics

Share